Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

Analysts fell to the sidelines weighing in on Avantor (AVTR) and Bristol-Myers Squibb (BMY) with neutral ratings, indicating that the experts are n...

Analysts Offer Insights on Healthcare Companies: Avantor (AVTR) and Bristol-Myers Squibb (BMY)

Artificial intelligence is helping bring medications to market. 


Bristol Myers Squibb (BMY) Adopts Nvidia’s AI Computing System for Drug Discoveries

Exchange-traded funds (ETFs) are a popular investment choice to gain diversified exposure to a wide range of asset classes and markets. They offer ...

Best ETFs to Invest In, According to AI Analyst, 7/15/2026

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) is launching a Phase III lu...

BMY’s IZABRIGHT-Lung02 Trial Targets Growth in EGFR Lung Cancer

Bloomsbury Publishing ( ($GB:BMY) ) has shared an update. Bloomsbury Publishing PLC reported that all resolutions at its 2026 Annual General Meetin...

Bloomsbury Investors Back All Resolutions at 2026 AGM

Berenberg Bank analyst reiterated a Buy rating on Bloomsbury Publishing today and set a price target of p825.00. The word on The Street in general,...

Berenberg Bank Sticks to Their Buy Rating for Bloomsbury Publishing (BMY)

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. Bansal c...

Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ANI Pharmaceuticals (ANIP), Bristol-Myers Squibb (BM...

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Bristol-Myers Squibb (BMY) and Delcath Systems (DCTH)

Stocks ended the week lower as investors pulled back from risk assets and rotated into safer parts of the market. The Dow Jones Industrial Average ...

The Week That Was, The Week Ahead: Macro and Markets, June 28

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a new study in Japan calle...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$62.44	+1.50%	3.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$62.44	+1.5%	3.63M
3
4
5
6

BMY

BMY

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel